Radium-223 Enhances Outcomes with Enzalutamide in Metastatic Castration-Resistant ...

Combining radium-223 with enzalutamide significantly extended radiological progression-free survival and overall survival in advanced prostate cancer patients with bone metastases, according to the PEACE-3 trial. A bone-protecting agent is mandatory when using this combination. The median radiological progression-free survival was 19.4 months in the combination arm vs 16.4 months in the enzalutamide-only arm. Median overall survival was 42.3 months vs 35.0 months, respectively.